Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2020

01-12-2020 | Public Health | Research Article

Direct patient care services by community and ambulatory care pharmacists in Idaho

Authors: Elaine Nguyen, John T. Holmes, Radhika Narsinghani, Shanna O’Connor, Matthew W. Fuit, Lynn Thaden, Renee Robinson

Published in: International Journal of Clinical Pharmacy | Issue 6/2020

Login to get access

Abstract

Background Pharmacists are one of the most accessible but unoptimized healthcare providers in the community. They are medication experts and have authority to independently prescribe in Idaho. Through the provision of direct patient care services (i.e., those distinct from traditional prescription dispensing functions), pharmacists have a greater opportunity to impact chronic disease prevention and management across the state. This can be done by filling gaps in community care (e.g., prescribing recommended therapy) and directly managing and preventing chronic diseases. However, current practices surrounding pharmacist-provided direct patient care services are unknown. Objective To characterize direct patient care services provided by Idaho community and ambulatory care pharmacists as well as to assess individual pharmacists’ and their work sites’ capacity and barriers in providing and expanding services. Setting Community and ambulatory care pharmacists’ work sites in Idaho. Method We administered a cross-sectional, electronic, 20-min survey to Idaho community and ambulatory care pharmacists. Main outcome measure The survey focused on collecting data on current practices, capacity, and barriers related to pharmacist-provided direct patient care services. Results The survey was completed by 280 eligible community and ambulatory care pharmacists with the majority of respondents (n = 250) offering pharmacist-provided direct patient care services. Pharmacists most often prescribed therapy for tobacco cessation (nicotine replacement, bupropion, varenicline), naloxone, and devices for patients with diabetes. Top barriers to individual pharmacists providing services were dispensing load and workload while top barriers to work sites (e.g., environment) were reimbursement/billing, number of available staff, and workflow. Conclusion Idaho community and ambulatory care pharmacists currently offer direct patient care services to patients across the state, but face barriers in providing and increasing services offered.
Appendix
Available only for authorised users
Literature
2.
go back to reference American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabet Care. 2018;41(5):917–28.CrossRef American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabet Care. 2018;41(5):917–28.CrossRef
3.
go back to reference Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.CrossRefPubMed Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.CrossRefPubMed
7.
go back to reference Yap D. Idaho pharmacists can prescribe more than 20 categories of medications. Pharmacy Today. 2018;24(10):44–5.CrossRef Yap D. Idaho pharmacists can prescribe more than 20 categories of medications. Pharmacy Today. 2018;24(10):44–5.CrossRef
8.
go back to reference Adams AJ, Weaver KK. The continuum of pharmacist prescriptive authority. Ann Pharmacother. 2016;50(9):778–84.CrossRefPubMed Adams AJ, Weaver KK. The continuum of pharmacist prescriptive authority. Ann Pharmacother. 2016;50(9):778–84.CrossRefPubMed
13.
go back to reference Sabater-Hernandez D, Sabater-Galindo M, Fernandez-Llimos F, Rotta I, Hossain LN, Durks D, et al. A systematic review of evidence-based community pharmacy services aimed at the prevention of cardiovascular disease. J Manag Care Spec Pharm. 2016;22(6):699–713.PubMed Sabater-Hernandez D, Sabater-Galindo M, Fernandez-Llimos F, Rotta I, Hossain LN, Durks D, et al. A systematic review of evidence-based community pharmacy services aimed at the prevention of cardiovascular disease. J Manag Care Spec Pharm. 2016;22(6):699–713.PubMed
14.
go back to reference Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsey E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.CrossRefPubMed Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsey E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.CrossRefPubMed
15.
go back to reference Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Care. 2012;35(12):2706–17.CrossRef Santschi V, Chiolero A, Paradis G, Colosimo AL, Burnand B. Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Care. 2012;35(12):2706–17.CrossRef
16.
go back to reference Charrois TL, Zolezzi M, Koshman SL, Pearson G, Makowsky M, Durect T, et al. A systematic review of the evidence for pharmacist care of patient with dyslipidemia. Pharmacotherapy. 2012;32(3):222–33.CrossRefPubMed Charrois TL, Zolezzi M, Koshman SL, Pearson G, Makowsky M, Durect T, et al. A systematic review of the evidence for pharmacist care of patient with dyslipidemia. Pharmacotherapy. 2012;32(3):222–33.CrossRefPubMed
17.
go back to reference Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78(6):1238–47.CrossRefPubMedPubMedCentral Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78(6):1238–47.CrossRefPubMedPubMedCentral
18.
go back to reference Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, et al. Pharmacist-led medication review in community settings: an overview of systematic reviews. Res Social Adm Pharm. 2017;13(4):661–85.CrossRefPubMed Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, et al. Pharmacist-led medication review in community settings: an overview of systematic reviews. Res Social Adm Pharm. 2017;13(4):661–85.CrossRefPubMed
23.
go back to reference American Society of Health-System Pharmacists. ASHP statement on the role of health-system pharmacists in public health. Am J Health-Syst Pharm. 2008;65(5):462–7.CrossRef American Society of Health-System Pharmacists. ASHP statement on the role of health-system pharmacists in public health. Am J Health-Syst Pharm. 2008;65(5):462–7.CrossRef
24.
go back to reference Gebbie K, Merrill J, Tilson HH. The public health workforce. Health Aff. 2002;21(6):57–67.CrossRef Gebbie K, Merrill J, Tilson HH. The public health workforce. Health Aff. 2002;21(6):57–67.CrossRef
25.
go back to reference Watson T, Hughes C. Pharmacists and harm reduction: a review of current practices and attitudes. Can Pharm J. 2012;145(3):124–7.CrossRef Watson T, Hughes C. Pharmacists and harm reduction: a review of current practices and attitudes. Can Pharm J. 2012;145(3):124–7.CrossRef
26.
go back to reference American Society of Health-System Pharmacists. ASHP guidelines on the pharmacist’s role in immunization. Am J Health-Syst Pharm. 2003;60(13):1371–7.CrossRef American Society of Health-System Pharmacists. ASHP guidelines on the pharmacist’s role in immunization. Am J Health-Syst Pharm. 2003;60(13):1371–7.CrossRef
28.
go back to reference Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The role of pharmacists in the opioid epidemic: an examination of pharmacist-focused initiatives across the United and North Carolina. N C Med J. 2017;78(3):202–5.PubMed Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The role of pharmacists in the opioid epidemic: an examination of pharmacist-focused initiatives across the United and North Carolina. N C Med J. 2017;78(3):202–5.PubMed
29.
go back to reference Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Adm Pharm. 2019;15(8):910–6.CrossRefPubMed Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Adm Pharm. 2019;15(8):910–6.CrossRefPubMed
30.
go back to reference Thaku R, Frey M, Chewning B. Pharmacist services in the opioid crisis: current practices and scope in the United States. Pharmacy. 2019;7(2):pii E60.CrossRef Thaku R, Frey M, Chewning B. Pharmacist services in the opioid crisis: current practices and scope in the United States. Pharmacy. 2019;7(2):pii E60.CrossRef
36.
go back to reference Wadsworth TG, Hibbard A, Robinson R, Biddle MA, Nguyen E, O’Connor S, et al. Pharmacist medical provider status in Alaska, the last frontier. J Am Pharm Assoc. 2020;S1544–3191(20):30155-2. Wadsworth TG, Hibbard A, Robinson R, Biddle MA, Nguyen E, O’Connor S, et al. Pharmacist medical provider status in Alaska, the last frontier. J Am Pharm Assoc. 2020;S1544–3191(20):30155-2.
38.
go back to reference Spiro S. Digital transformation of pharmacists’ clinical services. J Am Pharm Assoc. 2019;59(2S):S8–12.CrossRef Spiro S. Digital transformation of pharmacists’ clinical services. J Am Pharm Assoc. 2019;59(2S):S8–12.CrossRef
39.
go back to reference Nguyen E, Holmes JT. Pharmacist-provided services: barriers to demonstrating value. J Am Pharm Assoc. 2019;59(1):117–20.CrossRef Nguyen E, Holmes JT. Pharmacist-provided services: barriers to demonstrating value. J Am Pharm Assoc. 2019;59(1):117–20.CrossRef
Metadata
Title
Direct patient care services by community and ambulatory care pharmacists in Idaho
Authors
Elaine Nguyen
John T. Holmes
Radhika Narsinghani
Shanna O’Connor
Matthew W. Fuit
Lynn Thaden
Renee Robinson
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 6/2020
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01130-0

Other articles of this Issue 6/2020

International Journal of Clinical Pharmacy 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.